Results 101 to 110 of about 1,131 (155)

Systemic therapies for medullary thyroid carcinoma: state of the art. [PDF]

Ther Adv Endocrinol Metab
Román-González A, Califano I, Concepción-Zavaleta M, Pitoia F, Salgado SA.   +4 more
europepmc   +1 more source

Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review. [PDF]

Neurooncol Pract
Huijs JWJ, Bortolot M, Berghoff AS, Brastianos PK, Degens JHRJ, De Ruysscher DKM, Compter A, Hendriks LEL.   +7 more
europepmc   +1 more source

Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. [PDF]

Oncologist
McKinley BJ, Coston TW, Starr JS.
europepmc   +1 more source

Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. [PDF]

ESMO Open
Raez LE, Kang H, Ohe Y, Khanal M, Han Y, Szymczak S, Barker SS, Gilligan AM.   +7 more
europepmc   +1 more source

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Pérol M, Solomon BJ, Goto K, Park K, Nadal E, Bria E, Martin C, Bar J, Williams JN, Puri T, Li J, Uh MK, Lin BK, Zhou C.   +13 more
europepmc   +1 more source

Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series. [PDF]

Biomedicines
Mormando M, Lauretta R, Puliani G, Bianchini M, Spoltore ME, Appetecchia M.   +5 more
europepmc   +1 more source

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications. [PDF]

Int J Mol Sci
Theik NWY, De Armas SA, Rosas D, Kiamos A, Thaw Dar NN, Shoreibah A, Hussein A, Raez LE.   +7 more
europepmc   +1 more source

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

J Clin Endocrinol Metab
Deschler-Baier B, Konda B, Massarelli E, Hu MI, Wirth LJ, Xu X, Wright J, Clifton-Bligh RJ.   +7 more
europepmc   +1 more source

Lung Cancer: Targeted Therapy in 2025. [PDF]

Curr Oncol
Bouchard N, Daaboul N.
europepmc   +1 more source

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. [PDF]

NPJ Precis Oncol
Deschler-Baier B, Krebs M, Kroiss M, Chatterjee M, Gundel D, Kestler C, Kerscher A, Kunzmann V, Appenzeller S, Maurus K, Rosenwald A, Bargou R, Gerhard-Hartmann E, Venkataramani V.   +13 more
europepmc   +1 more source